Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
113 words
An optically active or racemic 13-thia-prostacycline of the Formula I ##STR9## wherein R 1 is hydrogen, a pharmaceutically acceptable cation or a straight or branched chain alkyl group having 1-5 carbon atoms; R 2 is straight or branched chain alkyl having 4-9 carbon atoms or is phenoxymethyl substituted by a halo or a trifluoromethyl substituent: --A--B-- is --CH 2 --CH 2 --, --CH═CH-- of Z- or E-configuration or --C.tbd.C; one of the symbols X and Y is hydrogen, methyl or ethyl and the other is hydroxy, tetrahydropyranyloxy, 1-ethoxy-ethoxy or trialkylsilyloxy; or X and Y together form a --O--CH 2 --CH 2 --O-- group; and Z is a sulfur atom or a --SO-- group.
Claim 2
Dependent Claim
113 words
An optically active or racemic 13-thia-prostacycline of the Formula I ##STR9## wherein R 1 is hydrogen, a pharmaceutically acceptable cation or a straight or branched chain alkyl group having 1-5 carbon atoms; R 2 is straight or branched chain alkyl having 4-9 carbon atoms or is phenoxymethyl substituted by a halo or a trifluoromethyl substituent: --A--B-- is --CH 2 --CH 2 --, --CH═CH-- of Z- or E-configuration or --C.tbd.C; one of the symbols X and Y is hydrogen, methyl or ethyl and the other is hydroxy, tetrahydropyranyloxy, 1-ethoxy-ethoxy or trialkylsilyloxy; or X and Y together form a --O--CH 2 --CH 2 --O-- group; and Z is a sulfur atom or a --SO-- group.
Claim 3
Dependent Claim
9 words
13-thia-13,14-dihydro-PGI 2 -methyl ester as defined in claim 1.
Claim 4
Dependent Claim
9 words
15-epi-13-thia-13,14-dihydro-PGI 2 -methyl ester as defined in claim 1.
Claim 5
Dependent Claim
11 words
13-thia-13,14-dihydro-15-dehydro-PGI 2 -methyl ester ethylene ketal as defined in claim 1.
Claim 6
Dependent Claim
10 words
Sodium salt of 13-thia-13,14-dihydro-PGI 2 as defined in claim 1.
Claim 7
Dependent Claim
33 words
A pharmaceutical composition having blood platelet aggregation inhibitory effect comprising as active ingredient a pharmaceutically effective amount of at least one compound in claim 1 in admixture with suitable inert non-toxical pharmaceutical carriers.
Claim 8
Dependent Claim
28 words
A method of treatment for blood platelet aggregation inhibiting effect which comprises administering to a susceptible subject an effective amount of a compound as defined in claim 1.
Claim 9
Dependent Claim
114 words
A compound of the formula II ##STR10## wherein R 1 is hydrogen, a pharmaceutically acceptable cation, or a straight or branched chain alkyl group having 1-5 carbon atoms; R 2 is straight or branched chain alkyl having 4 to 9 carbon atoms or is phenoxymethyl substituted by a halo or a trifluoromethyl substituent; --A--B-- is --CH 2 --CH 2 --, --CH═CH-- of Z- or E-configuration or --C.tbd.C--; one of the symbols X and Y is hydrogen, methyl or ethyl and the other is hydroxy, tetrahydropyranyloxy, 1-ethoxy-ethoxy, or trialkylsilyloxy; or X and Y together form a --O--CH 2 --CH 2 --O-- group; Z is a sulfur atom or a --SO-- group, and E is halogen.
Claim 10
Dependent Claim
114 words
A compound of the formula II ##STR10## wherein R 1 is hydrogen, a pharmaceutically acceptable cation, or a straight or branched chain alkyl group having 1-5 carbon atoms; R 2 is straight or branched chain alkyl having 4 to 9 carbon atoms or is phenoxymethyl substituted by a halo or a trifluoromethyl substituent; --A--B-- is --CH 2 --CH 2 --, --CH═CH-- of Z- or E-configuration or --C.tbd.C--; one of the symbols X and Y is hydrogen, methyl or ethyl and the other is hydroxy, tetrahydropyranyloxy, 1-ethoxy-ethoxy, or trialkylsilyloxy; or X and Y together form a --O--CH 2 --CH 2 --O-- group; Z is a sulfur atom or a --SO-- group, and E is halogen.
Claim 11
Dependent Claim
11 words
5-iodo-13-thio-13, 14-dihydro-PGI 1 , -methyl ester, as defined in claim 8.
Claim 12
Dependent Claim
9 words
15-epi-5-iodo-13-thia-13,14-dihydro-PGI 1 -methyl ester, as defined in claim 8.
Claim 13
Dependent Claim
12 words
5-iodo-13-thia-13, 14-dihydro-15-dehydro-PGI 1 -methyl ester ethylene ketal, as defined in claim 8.